(S)-Oxiracetam | CAS#88929-35-5 | AMPA receptor modulator

MedKoo Cat#: 561589 | Name: (S)-Oxiracetam

Featured

Description:

WARNING: This product is for research use only, not for human or veterinary use.

(S)-Oxiracetam is a positive allosteric modulator of the AMPA receptors.

Chemical Structure

(S)-Oxiracetam

CAS#88929-35-5

Theoretical Analysis

MedKoo Cat#: 561589

Name: (S)-Oxiracetam

CAS#: 88929-35-5

Chemical Formula: C6H10N2O3

Exact Mass: 158.0691

Molecular Weight: 158.15

Elemental Analysis: C, 45.57; H, 6.37; N, 17.71; O, 30.35

Price and Availability

Size	Price	Availability	Quantity
10mg	USD 650.00

Bulk Inquiry

Buy Now

Add to Cart

Related CAS #

No Data

Synonym

(S)-Oxiracetam; S-Oxiracetam; (S)-ISF-2522;

IUPAC/Chemical Name

2-[(4S)-4-hydroxy-2-oxopyrrolidin-1-yl]acetamide

InChi Key

IHLAQQPQKRMGSS-BYPYZUCNSA-N

InChi Code

InChI=1S/C6H10N2O3/c7-5(10)3-8-2-4(9)1-6(8)11/h4,9H,1-3H2,(H2,7,10)/t4-/m0/s1

SMILES Code

O=C(N)CN1C(C[C@H](O)C1)=O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>2 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 158.15 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Liang D, Shen J, Jia Y, Dai M, Li X, Zhou L, Wang W, Yang B, Shao J, Jiang Y, Xie H, Sun H. Pharmacokinetic Properties of S-oxiracetam After Single and Multiple Intravenous Infusions in Healthy Volunteers. Eur J Drug Metab Pharmacokinet. 2021 Nov;46(6):793-805. doi: 10.1007/s13318-021-00718-9. Epub 2021 Sep 21. PMID: 34549388. 2: Fan W, Zhang Y, Li X, Xu C. S-oxiracetam Facilitates Cognitive Restoration after Ischemic Stroke by Activating α7nAChR and the PI3K-Mediated Pathway. Neurochem Res. 2021 Apr;46(4):888-904. doi: 10.1007/s11064-021-03233-0. Epub 2021 Jan 22. PMID: 33481205. 3: Fan W, Li X, Huang L, He S, Xie Z, Fu Y, Fang W, Li Y. S-oxiracetam ameliorates ischemic stroke induced neuronal apoptosis through up-regulating α7 nAChR and PI3K / Akt / GSK3β signal pathway in rats. Neurochem Int. 2018 May;115:50-60. doi: 10.1016/j.neuint.2018.01.008. Epub 2018 Jan 19. PMID: 29355569. 4: Wang W, Ji H, Li T, Jia Y, Xie H. Pharmacokinetic comparisons of S-oxiracetam and R-oxiracetam in beagle dogs. Acta Pharm. 2016 Jun 1;66(2):279-87. doi: 10.1515/acph-2016-0013. PMID: 27279070. 5: Liu TT, Guo XM, Rong ZY, Ye XF, Wei JF, Wang AP, Jin HT. Comparative toxicity and toxicokinetic studies of oxiracetam and (S)-oxiracetam in dogs. Xenobiotica. 2019 Sep;49(9):1054-1062. doi: 10.1080/00498254.2018.1528027. Epub 2019 Jan 4. PMID: 30351213. 6: Wang C, Dong H, Liu H, Sun Z, Yuan A, Wu J, Hu Y. Using HPLC to analyze (S)-oxiracetam and four related substances in the bulk drug of (S)-oxiracetam. J Pharm Biomed Anal. 2020 Feb 20;180:113072. doi: 10.1016/j.jpba.2019.113072. Epub 2019 Dec 23. PMID: 31891873. 7: Li W, Liu H, Jiang H, Wang C, Guo Y, Sun Y, Zhao X, Xiong X, Zhang X, Zhang K, Nie Z, Pu X. (S)-Oxiracetam is the Active Ingredient in Oxiracetam that Alleviates the Cognitive Impairment Induced by Chronic Cerebral Hypoperfusion in Rats. Sci Rep. 2017 Aug 30;7(1):10052. doi: 10.1038/s41598-017-10283-4. PMID: 28855592; PMCID: PMC5577264. 8: Huang L, Shang E, Fan W, Li X, Li B, He S, Fu Y, Zhang Y, Li Y, Fang W. S-oxiracetam protect against ischemic stroke via alleviating blood brain barrier dysfunction in rats. Eur J Pharm Sci. 2017 Nov 15;109:40-47. doi: 10.1016/j.ejps.2017.07.029. Epub 2017 Jul 29. PMID: 28760594. 9: Zhang T, Tao Y, Pu J, Zhu M, Wan L, Tang C. Safety, tolerability, and pharmacokinetics of oral (S)-oxiracetam in Chinese healthy volunteers: A randomized, double-blind, controlled phase I study. Eur J Pharm Sci. 2024 Jan 1;192:106621. doi: 10.1016/j.ejps.2023.106621. Epub 2023 Oct 28. PMID: 37898393. 10: Wang Y, Liu Y, Sha Y, Li J, Han L, Chen H, Su S, Li N, Chen X, Zhao D. Development and validation of a chiral UPLC-MS/MS method for quantifying S-Oxiracetam and R-Oxiracetam in human plasma, urine and feces: Application to a phase-I clinical pharmacokinetic study. J Pharm Biomed Anal. 2024 Feb 15;239:115881. doi: 10.1016/j.jpba.2023.115881. Epub 2023 Nov 30. PMID: 38101242. 11: Zhang Q, Yang W, Zhang Q, Yang Y, Li J, Lu Y, Zheng Y, He J, Zhao D, Chen X. Enantioselective HPLC determination of oxiracetam enantiomers and application to a pharmacokinetic study in beagle dogs. J Chromatogr B Analyt Technol Biomed Life Sci. 2015 Jul 1;993-994:9-13. doi: 10.1016/j.jchromb.2015.04.033. Epub 2015 Apr 30. PMID: 25978861.